Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will engineer Optimer binders as targeted radiopharmaceuticals for potential therapeutic applications.
October 8, 2025
By: Charlie Sternberg
Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a significant development contract with a top 3 global pharmaceutical company to engineer Optimer binders as targeted radiopharmaceuticals for potential therapeutic applications.
Dr Arron Tolley, CEO of Aptamer Group, said: “This significant contract win with a top 3 global pharmaceutical company marks a key expansion of our platform into targeted radiopharmaceuticals and potential therapeutics.”
The new £360,000 ($483,000) fee-for-service development contract is to develop Optimer binders as targeted radiopharmaceuticals with potential applications in therapeutics. Aptamer retains rights for future licensing revenues upon commercialization, positioning the Company for future downstream licensing and/or royalty revenue streams.
This program will engineer Optimers targeting an undisclosed cancer target. Preliminary work will develop tools for Positron Emission Tomography (PET) imaging with a view to translating to therapeutic applications. The Optimer platform offers advantages for this application area, including enhanced tumor penetration, reduced immunogenicity, and ease of chemical optimization.
The contract expands the application of the Company’s Optimer technology into the growing targeted radiopharmaceuticals market, valued at $7.5 billion in 2025, and represents the second therapeutic modality under development by Aptamer alongside targeted gene therapy.
Aptamer entered two other development contracts for its Optimer binders earlier this year.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
